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1. Introduction 
1.1 The Nasopharynx (an unusual perspective of a peculiar structure) 
Nasopharynx is a peculiar anatomic structure with an essential role in respiratory, digestive 
and auditory systems. It is located between the respiratory and digestive tracts and its 
anatomic and physiologic characteristics depend on complex and not totally explained 
phylogenic, ontogenic and embryologic factors. Some of these factors demonstrated to be 
relevant not only on the pathogenesis, characteristics and development of nasopharyngeal 
carcinoma (NPC), but also on therapeutic options and their implications (Breda, Catarino et 
al. 2008).  
In what concerns to phylogenic aspects, it is important to emphasize that either in chordates 
as even in the first aquatic vertebrates (agnate), the upper aerodigestive and respiratory 
tracts were associated, providing both the oxygenation and feeding supplies needed in an 
aquatic environment. However, according to Everett C. Olson (Rainger 1997), the appraisal 
of the oxygen and nourish requirements requested by the tetrapods, demanded the taking 
apart of oronasal cavity and the formation of primitive choanae; this was performed by the 
expansion of the branchial arches and the development of the mandible. Interestingly, this 
original functional ambivalence persists in mammals, and is visible in their anatomic 
relationships: nasal cavity is in a dorsal position relatively to the oral cavity but the larynx 
diverges ventrally from the pharynx. 
In humans, as in most mammalians, pharyngeal and most of nasal cavity mucosa are the 
end result of a unique embryologic origin, depending from the cephalic portion of the 
primitive gut, a blind ending tube, lined with endodermic tissue, separated from the 
ectodermic stomatodeum by the buccopharyngeal membrane (Beasly 2008). Before the 
rupture of buccopharyngeal membrane happens, two recesses will form in this region: the 
Rathke pouch, which will origin the adenohypophysis and the Seesel pouch, representing 
the primordium of the future nasopharynx (Figure 1).  
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Fig. 1. Human embryo (about 3 weeks): 1 - notocordium; 2 - Tornwaldt pouch origin;  
3- Seesel pouch; 4 - Rathke pouch; 5 - buccopharyngeal membrane [Adapted from (Breda, 
Catarino et al. 2008)].  
The muscle and osseous components of nasopharynx will take origin from the 
viscerocranium (pharyngeal or branchial arches and clefts), and neurocranium (Saddlet 
1995). Pharyngeal arches contribute with mesenchymal tissue covered on the outside by 
surface ectoderm and on the inside by epithelium of endodermal origin. In addition, each 
arch receives substantial numbers of neural crest cells, which migrate into the arches to 
contribute to skeletal components of the face (Saddlet 2009). The development of Meckel 
cartilage is associated with a predominance of sagital craniofacial growth and increase of 
vertical and anterior-posterior length compared with transversal diameter. 
Nasopharyngeal osseous superior and posterior limits (body of the shpenoid bone and the 
basilar part of occipital bone united in the sphenobasilarsynchondrosis) are derived from 
the prechordal chondrocranium (cartilages lying in front of the rostral limit of the 
notochord, which ends at the level of the pituitary gland in the center of the sella turcica, 
derived from neural crest cells) and the chordal chondrocranium, composed by those 
cartilages that lie posterior to this limit and arise from occipital sclerotomes formed by 
paraxial mesoderm (Saddlet 2009).  
Intra-uterine increase of supratentorial and craniobasal angles and simultaneous shortness 
of infratentorial one (Jeffery 2005) contribute also to nasopharyngeal final shape, and these 
changes could be connected, according to Bull, to the development of occipital lobe, 
associated with bipedalism (Bull 1969) (Figure 2). 
 
Fig. 2. Ontogenic aspects of cranial morphogenesis: TSA – supratentorial angle; ITA – 
infratentorial angle;CBA – craniobasal angle; tc – cranial attachment of tentorium cerebelli;  
s – sella; fc – foramen caecum [Adapted from (Breda, Catarino et al. 2008)].  
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The nasopharynx is thus the end result of the several factors affecting its development, 
resulting in a trapezoid tubular about 128º angled structure, with average 4cm to 5,5cm 
transversal diameter, 2,5cm to 3,5cm anterior-posterior diameter e 4cm high(Snow Jr and 
Ballenger 2003). It has an anterior opening continuous with the posterior choanae and 
communicates with the oropharynx inferiorly, through a complex sphincteric mechanism. 
Superior wall is continuous with the posterior and in lateral walls an apparent Rosenmuller 
lateral pharyngeal recess posterior to the internal opening of pharyngotympanic tube are the 
main anatomic evidences.  
The nasopharyngeal wall is composed of mucous membrane (with pseudostratified 
columnar epithelium, “lamina propria”, lymphoid tissue and stem cells), pharyngobasilar 
fascia, muscle layer and buccopharyngeal fascia(Standring 2008).Immediately posterior lie 
the retropharyngeal lymph nodes, between this and the prevertebral fascia. 
When considering local anatomic implications on nasopharyngeal malignancies, the 
organization and function of lymphoid tissue, the potential oncologic relevance of stem cells 
and the significance of the cellular structure of the epithelium, muscles and neighboring 
salivary (minor and major) glands are examples of some topics waiting for answers.  
The mucosal immune system of upper aero-digestive tract provides the first line of defense 
against the ingress of microbial pathogens during the physiological processes of inhalation 
and ingestion. One of the major components of the mucosal immune system is secretory IgA 
(S-IgA),which is produced by the mucosal interaction of epithelial cells, IgA-committed B 
cells, and Th cells(Shikina, Hiroi et al. 2004).  
Nasopharynx-associated lymphoid tissue (NALT) plays a pivotal role in the initiation of Ag-
specific immune responses at both systemic and mucosal sites, acting acts as an important 
inductive site for the generation of Ag-specific IgA-committed B cells(Fukuyama, Nagatake 
et al. 2006). The relationship between NALT system and Epstein-Barr virus (EBV) infection 
is being studied. There is now increasing evidence that defects in the immune control of 
EBV infection are linked to EBV associated malignancies, namely Hodgkin’s disease and 
NPC, with the selective loss of EBV specific T cells and induction of local 
immunosuppressive microenvironment that favors tumor growth (Braz-Silva, Vitale et al. 
2011). 
In the identification of the malignant population that might be responsible for tumor 
initiation, the cancer stem cell (CSC) (Clarke, Dick et al. 2006), is other promising scientific 
advance. CSC is commonly assumed to have developed from a normal tissue stem cell. In 
normal organs, stem cells are defined as a subset of cells with the capacity of self-renewal to 
maintain the stem cell reservoir and of differentiation to generate various types of cells in 
the tissue. By self-renewal, stem cells divide symmetrically and perpetuate themselves by 
generating daughter cells with identical stem cell abilities of the parent. By differentiation, 
stem cells give rise to a hierarchy of limitedly proliferative but functional mature cells 
(Brady, Heilman et al. 2010). Zhang et al described for the first time stem cells in mouse 
nasopharyngeal epithelium; they represent less than 3% of cell population, and they lie 
mostly in basal and superbasal layers (Zhang, Wu et al. 1982). The polycomb group protein 
Bmi-1 is required for the maintenance and self-renewal of stem cells. The molecular 
mechanisms underlying the modulation of such stem-like cell populations in NPC remain 
unclear. However, according to Song et al (Song, Li et al. 2009), previous upregulation of 
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Bmi-1 correlates with invasion of NPC and otherwise a possible mechanism of 
tumorigenesis involves repression of the Ink4a-Arf locus, which encodes the tumor 
suppressors INK4A and ARF, by direct binding of Bmi-1. 
Furthermore, there is an ongoing debate over whether CSCs represent a mature tissue stem 
cell which has undergone malignant change or whether more differentiated cells re-initiate a 
‘stemness’ programme as part of, or following, malignant transformation (Bomken, Fiser et 
al. 2010).  
These and other questions are yet to be answered, namely how to explain the relationship 
between CSC, NPC and EBV. The recent accomplishment that LMP2A EBV encoded latent 
protein, induces epithelial–mesenchymal transition and stem-like cell self-renewal in NPC, 
is a strong evidence of this association (Kong, Hu et al. 2010). 
2. The Epstein Barr virus and mechanisms of infection 
Many epidemiological studies have been performed concerning NPC and three well-defined 
etiological factors involved in its pathogenesis have been identified. These include genetic 
susceptibility, early-age exposure to chemical carcinogens and an association with a latent 
EBV infection (Chan, Teo et al. 2002; Busson, Keryer et al. 2004). 
It is widely accepted that EBV infection plays a major role in the pathogenesis of NPC in 
endemic areas, although not entirely clear in non-endemic regions (Henle and Henle 1976; 
Pathmanathan, Prasad et al. 1995). The association between NPC and EBV was initially 
discovered from serological studies and was later supported by demonstration of EBV DNA 
and nuclear antigen proteins (EBNA) in NPC tumor cells (zur Hausen, Schulte-Holthausen 
et al. 1970; Henle and Henle 1976). The notion that EBV plays an important role in the 
development of NPC is further supported by the observation that early nasopharyngeal 
lesions (dysplasia or carcinoma-in situ) are already EBV-positive, harbouring latent and 
clonal viral genomes as well as viral oncoproteins such as latent membrane protein (LMP) 
(zur Hausen, Schulte-Holthausen et al. 1970; Pathmanathan, Prasad et al. 1995). 
In 1958, Denis Burkitt, a British surgeon working in Africa, described a common cancer 
primarily affecting children in specific regions of Africa (Burkitt 1958). Burkitt believed that 
a virus might be implicated in cancer development, given the climatic and geographic 
distribution of the cases (Burkitt 1962). EBV was first identified in 1964 when Anthony 
Epstein, Yvonne Barr and Bert Achong detected virus-like particles by electron microscopy 
in a cell line that had been established from a Burkitt’s lymphoma biopsy (Epstein, Achong 
et al. 1964). The causal link between EBV and BL was corroborated by evidence showing 
that BL patient sera had elevated antibodies to EBV antigens (Henle and Henle 1966) . This 
group also established a link between primary EBV infection and infectious mononucleosis 
and, subsequently, the association of EBV with nasopharyngeal carcinoma (Henle, Henle et 
al. 1968; Henle, Henle et al. 1970; zur Hausen, Schulte-Holthausen et al. 1970). 
Nasopharyngeal cancer, particularly when showing histological patterns of non-
keratinization (WHO/1978 II or III), is associated with previous EBV infection with 
sequential immortalization of the virus in the host’s B-lymphocytes (Niedobitek, Hansmann 
et al. 1991).  
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EBV is a member of the herpesvirus family. As other herpesviruses, EBV is an enveloped 
virus that contains a DNA core surrounded by an icosahedral nucleocapsid and a tegument. 
Family members include herpes simplex 1 (HSV-1) and 2 (HSV-2) and varicella-zoster virus 
(VZV) - alphavirus subfamily; cytomegalovirus (CMV) and human herpesvirus 6 (HHV-6) 
and 7 (HHV-7) - betaherpesvirus subfamily; and human herpesvirus 8 (HHV-8) and EBV - 
gammaherpesvirus subfamily. The oncogenic potential of EBV was recognized through the 
association with numerous human malignancies. In addition to endemic Burkitt’s 
lymphoma and NPC, EBV was later found in Hodgkin’s lymphoma cases, post-transplant 
lymphoproliferative diseases, some T-cell lymphomas and a proportion of gastric 
carcinomas (Young and Rickinson 2004). Research is currently ongoing to determine the role 
of EBV-encoded gene products in these different cellular environments in an attempt to 
understand the role that EBV plays in the pathogenesis of these malignancies. 
It is now known that EBV infects 90% of the world’s adult population. Although 
herpesviruses are ubiquitous in nature, humans are the only natural host for EBV. Upon 
infection, the individual remains a life-long carrier of the virus (Henle and Henle 1976). 
During acute infection, EBV seems to primarily infect and replicate in the stratified 
squamous epithelium of the oropharynx, followed by a latent infection of the B 
lymphocytes. EBV infection of B lymphocytes is thought to occur in the upper aerodigestive 
tract lymphoid organs and the virus persists in circulating memory B cells (Sixbey, Nedrud 
et al. 1984; Farrell 1995). Taking in account that EBV infection is a common event in the 
entire World, the reasons why only some individuals will develop EBV-related 
malignancies, are interesting aspects yet to clarify. 
Much of the known biology of EBV relates to its interaction with B-lymphocytes. This is 
mainly a result of the ability of EBV to readily infect and transform normal resting B-
lymphocytes in vitro, which also confirms the B-lymphotropic nature of this virus. EBV 
latent gene expression in various EBV-associated malignancies and EBV-derived cell lines 
has led to the identification of three different and distinct latency patterns. These latency 
patterns characterize a heterogeneous group of diseases and are based on EBV genome 
expression arrangements as the result of differential promoter activity influenced by host 
cell factors (Thompson and Kurzrock 2004; Young and Rickinson 2004). Latency type I is 
generally associated with Burkitt’s lymphoma and is characterized by expression of the 
EBV-encoded RNAs (EBERs) and the BamHI-A rightward transcripts (BARTs), in addition 
to EBV nuclear antigen-1 (EBNA1) expression. Latency type II is associated with NPC, 
gastric cancer and EBV-positive Hodgkin lymphoma and is characterized by expression of 
EBERs, BARTs, EBNA1 and the latent membrane proteins (LMP1, LMP2A and LMP2B). 
Latency type III is associated with lymphoblastoid cell lines and post-transplant 
lymphoproliferative diseases: the full range of latent gene products are expressed, including 
EBNAs 1, 2, 3A, 3B, 3C and -LP, the expression of all three latent membrane proteins (LMP1, 
LMP2A and LMP2B) and EBERs and BART RNAs. Although these classifications of latency 
are useful in characterizing the distinct gene expression patterns, they are by no means 
completely definitive (Thompson and Kurzrock 2004). In recent years, there has been 
increasing interest in the presence of different viral and cellular micro-RNAs in EBV-
infected B cells and epithelial cells. Future works should investigate the role of EBV-encoded 
micro-RNAs and its correlation with transcriptional regulation of both the viral and cellular 
genome. 
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Analysis of EBV in NPC tumors has revealed the presence of clonal EBV genomes, 
suggesting that these carcinomas arise from the clonal expansion of a single EBV-infected 
progenitor cell (Raab-Traub and Flynn 1986). Similar to most EBV-associated malignancies, 
the exact role of EBV in NPC pathogenesis remains poorly understood. Unlike EBV-
associated B cell tumors, where the virus is considered to be an initiating factor in the 
oncogenic process, virus infection in the context of NPC pathogenesis seems to act as a 
tumor-promoting agent. 
Recent studies investigated circulating tumor-derived EBV DNA in the blood of NPC 
patients. Using real-time PCR methodology, studies indicate that the level of pre-treatment 
EBV DNA has prognostic significance. Furthermore, post-treatment EBV DNA levels seem 
to be correlated with treatment response and overall survival of NPC patients (Lo, Chan et 
al. 2000; Lo, Leung et al. 2000; Lin, Chen et al. 2001; Chan, Lo et al. 2002). This methodology 
should be applied in large-scale trials as an approach for early disease diagnosis. 
3. Genetic basis of NPC 
The identification of genetic changes in pre-malignant lesions and NPC tumors has led to the 
proposal of a multi-step model for the pathogenesis of NPC. Genome-wide analyses of genetic 
alterations in NPC have identified consistent genetic losses on several chromosomal arms, 
including 3p, 9p, 9q, 11q, 14q and 16q. Recurrent chromosomal gains were also identified on 
chromosomes 1q, 3q, 8q, 12p and 12q (Chan, To et al. 2000; Chan, To et al. 2002; Lo and Huang 
2002). The most common genetic change seems to be the loss of chromosome regions on 9p21 
and 3p, which is thought to occur early during NPC pathogenesis (Hui, Lo et al. 2002). NPC 
carcinogenesis seems to develop in a step by step fashion, where the chromosomal alterations, 
such deletion, tumor suppressor gene inactivation and oncogene promotion, are associated 
with morphological changes in the cell (Young and Rickinson 2004) (Figure 3). 
 
Fig. 3. NPC carcinogenesis scheme. 
Although the precise role of these genetic alterations in NPC carcinogenesis remains to be 
clarified, these genetic changes may predispose nasopharyngeal cells to facilitate latent EBV 
infection and this seems to be a crucial event in the multi-step progression towards NPC.  
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The development and progression of NPC involves the accumulation of genetic alterations. 
Both genetic and epigenetic changes can affect the development of NPC, by altering the 
function of genes that are critical for proliferation, apoptosis and differentiation. 
Host factors previously shown to be associated with NPC development include HLA class I 
and II alleles and polymorphisms of genes responsible for critical cellular functions, as 
carcinogen metabolism and detoxification, cell cycle control, DNA repair and immune 
response. Published studies demonstrated that some genetic variations are associated with a 
higher risk of NPC development (Hildesheim, Anderson et al. 1997; Nazar-Stewart, 
Vaughan et al. 1999; Cho, Hildesheim et al. 2003; Catarino, Breda et al. 2006; Sousa, Santos et 
al. 2006). This genetic predisposition to NPC may be modulated by environmental factors 
and this may have a differential impact in endemic and non-endemic NPC.  
Familial clustering of the disease has been widely documented in the Chinese population 
and several polymorphisms have been associated with NPC development, namely in 
nitrosamine metabolizing genes cytochrome P450 2A6 (CYP2A6), P450 2E1 (CYP2E1) and 
P450 2F1 (CYP2F1), Glutathione S- transferase M1 (GSTM1), XRCC1 (codons 194 arg-trp), 
have been suggested to influence the susceptibility to NPC (Hildesheim and Levine 1993; 
Pathmanathan, Prasad et al. 1995; Sousa, Santos et al. 2006; Tiwawech, Srivatanakul et al. 
2006).  
Less in known in non-endemic areas, but it has been suggested that the individual genetic 
background may influence the onset of NPC, also in these regions. Regarding cell cycle 
control, some studies investigated the role of polymorphisms in cyclin D1 (CCND1) and 
TP53 genes in the genetic susceptibility to NPC (Pathmanathan, Prasad et al. 1995; Cho, 
Hildesheim et al. 2003; Catarino, Pereira et al. 2008). These genetic variants have been 
associated with increased individual risk of NPC development. Regarding the key regulator 
of cell cycle, cyclin D1, the study by Catarino et al, demonstrate that individuals carrying the 
genetic variant present a 2-fold increased risk for the development of NPC, the proportion 
of cases attributable to the genotype being 14.76% (Catarino, Breda et al. 2006). Moreover, 
another study indicates that cyclin D1 variants influence the age of onset of oncogenic virus-
associated cancers, namely NPC (Catarino, Pereira et al. 2008). The results of this study 
demonstrate that the waiting time for onset of oncogenic virus-associated neoplasia in 
patients carrying the cyclin D1 variant was 12 years earlier in comparison with the other 
patients. Another study by Sousa et al, focus on the polymorphic variants (Arg/Pro) on 
TP53 codon 72 in nasopharyngeal cancer development. This study revealed a three-fold risk 
for carriers of Pro/Pro genotype, suggesting that Pro/Pro genotype represents a stable risk 
factor for nasopharyngeal carcinoma (Sousa, Santos et al. 2006). 
Another study revealed that a MDM2 polymorphism is associated with increased risk to 
develop NPC adjusted for age and gender, with particular effect in undifferentiated types 
and early clinical stages. The study also indicates that the median age of onset of NPC was 
significantly different according to the genetics variants (Sousa, Pando et al. 2011). 
Regarding the immune response markers, a study revealed an increased frequency of a 
tumor necrosis factor-alpha (TNF-α) polymorphic variant in patients with NPC. The authors 
indicate that this variant is associated with a 2-fold increased risk for the development of 
this disease. Moreover, this effect seems to be stronger in undifferentiated types (Sousa, 
Breda et al. 2011).  
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These results performed in low-risk, non-endemic areas indicate that these genetic 
variations may represent risk markers for NPC and contribute to the definition of genetic 
susceptibility profiles for the development of this disease. Furthermore, the knowledge of 
the mechanisms involved in NPC carcinogenesis may help to identify targets for the 
development of chemoprevention or therapeutic strategies. 
4. The Nasopharyngeal Carcinoma (NPC) 
4.1 NPC histopathologic classification (final clarification?) 
The histopathologic designation of this kind of tumor is matter of debate since the first 
description of “Primary Carcinoma of Nasopharynx”, performed by Chevalier Jackson 
(1901) based upon the description of 14 cases(Jackson 1901; Van Hasselt and Gibb 1999). 
From that time on, several designations have been used to designate this tumor, namely 
lymphoepithelioma, lymphoepitheliomalike carcinoma, lymphoepithelial carcinoma, 
Schmincke type lymphoepithelioma, Regaud type lymphoepithelioma, transitional cell 
carcinoma, intermediate cell carcinoma, anaplastic carcinoma, undifferentiated carcinoma 
with lymphoid stroma, vesicular nucleus cell carcinoma, and so on. 
This controversy seems to be solved with the WHO (2003) classification of NPC into three 
histologic types: keratinizing squamous carcinoma, nonkeratinizing carcinoma and basaloid 
carcinoma (IARC 2005).  
 
Fig. 4. Keratinizing squamous carcinoma. 
In keratinizing squamous carcinoma, the polygonal and stratified tumor cells grow in the 
form of irregular islands, accompanied by an abundant desmoplastic stroma infiltrated by 
variable numbers of lymphocytes, plasma cells, neutrophils and eosinophils. The cell 
borders are distinct and separated by intercellular bridges and possess abundant cytoplasm 
and small hiperchromatic nucleus. Often keratin pearls can be seen (Figure 4). 
Oppositely, the undifferentiated subtype of nonkeratinizing carcinoma is characterized by 
syncytial-appearing large tumor cells with indistinct cell borders, round to oval vesicular 
nuclei, and large central nucleoli, scanty cytoplasm. Often immunostaining for cytokeratins 
(eg MNF116) is needed to demonstrate the epithelial nature of the tumor (Figure 5). 
WHO (2003) classification recognizes the behavior similarities between diferentiated and 
undiferentiated subtypes of nonkeratinizing carcinoma (type II and III of the previous WHO 
classification-1978) (IARC 2005). Accordingly, there is clinical, histopathologic and 
immunologic evidence that nasopharyngeal carcinomas constitute two distinct diseases, 
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keratinizing squamous carcinoma in one side and nonkeratinizing carcinoma in the other, 
this later being linked to previous infection by Epstein–Barr virus.  
 
Fig. 5. The undifferentiated subtype of NPC. 
However, IARC “WHO Classification of Head and Neck Tumors” (IARC 2005), also 
describes 6 cases of basaloid squamous cell carcinoma (BSCC) arising as primary tumors of 
the nasopharynx. These tumors demonstrated to be morphologically identical to the same 
tumors more commonly occurring in other head and neck sites (larynx, hypopharynx and 
oropharynx) (Ereno, Gaafar et al. 2008), strongly associated with traditional risk factors, 
such as tobacco and alcohol abuse. 
BSCC of the upper aerodigestive tract was originally described by Wain et al (1986) (Wain, 
Kier et al. 1986), as a rare variant of squamous cell carcinoma, is characterized by clinically 
aggressive behavior and worse prognosis, independent of tumor stage. Two major 
histopathologic features define BSCC. Morphologically, BSCC also possess distinct 
histological features, presenting basaloid tumor cells (solid, lobular, small, crowded cells 
with scant cytoplasm, hyperchromatic round nuclei, and small cystic spaces containing 
PAS-or alcian blue–positive myxoid material) in a festooning growth pattern, interspersed 
by tumor cells with squamous differentiation (Chernock, Lewis et al. 2010). 
These histopathologic features are also very similar with those of oropharyngeal human 
papillomavirus (HPV)–related nonkeratinizing squamous cell carcinoma (NK SCC). This 
kind of carcinoma occurs predominantly in the tonsillar tissue of the oropharynx, in 
younger patients and have unique risk factors related to sexual behavior, including multiple 
partners, early age at first intercourse, and oral sex (Chernock, El-Mofty et al. 2009). The 
tumor appears to show a lower clinical aggressiveness compared with basaloid squamous 
cell carcinoma occurring in other head and neck sites (Begum and Westra 2008).  
The analogy between viral etiology and histomorphological characteristics of tumor  
development  site (close relationship between epithelium and lymphoid tissue) in HPV–
related”basaloid” NK SCC of oropharynx and NPC nonkeratinizing carcinoma EBV-related, 
seems to be quite obvious, but not completely clarified, and so are their  histopathologic 
patterns.  
4.2 NPC commented epidemiologic data 
Considering all nasopharyngeal tumors, the probability of being originated in the epithelial 
lining varies from 75 to 95% in low-risk populations, and all of them are virtually cancers in 
high-risk population (Parkin DM 2002). NPC is a patchy worldwide malignant disease, 
characterized by remarkable divergence in incidences among populations of diverse 
www.intechopen.com
 
Carcinogenesis, Diagnosis, and Molecular Targeted Treatment for Nasopharyngeal Carcinoma 
 
236 
geographic regions and races. It is very common in southern Asia (20-30/100 000 
inhabitants/year) (Vasef, Ferlito et al. 1997) and quite rare in western countries (<1/100 000 
inhabitants/year) (Parkin DM 2002). Intermediate incidence (8-12/100000 inhabitants/year) 
occurs in certain African and Mediterranean populations (Cvitkovic, Bachouchi et al. 1991) 
and also in the Inuits from Greenland and Alaska and Malays from Singapore and Malaysia. 
The relative percentage of NPC types according to the WHO classification seems to vary 
accordingly to the geographic distribution with about 95% rates of nonkeratinizing 
carcinoma in endemic regions (Wenig 1999) and 75% of keratinizing squamous carcinoma in 
countries with low prevalence of the disease, as in United States of America (Marks, Phillips 
et al. 1998). As far as we know, there is no European statistics dealing about this point, and 
online search at the GLOBACAN, doesn’t discriminate these histopathologic types. 
However detailed studies in a non-endemic European country (Portugal), reveal that in this 
population the relative rate of nonkeratinizing/keratinizing carcinoma is closer to the 
findings obtained in endemic countries (Breda, Catarino et al. 2007; d'Espiney Amaro, 
Montalvao et al. 2009) (Table 1). These findings suggest that studies envisaging the possible 
rearrangement of the relative weight of the different NPC types in European populations 
are needed. 
 
Nasopharyngeal Carcinoma in Portugal (age, sex and histopathologic distribution) 
INSTITUTION N. PATIENTS
AVERAGE AGE 
(years) 
GENDER (%) 
m/f 
WHO TYPE II/III 
(%) 
IPO-PORTO 320 48 67/33 93,75% 
IPO-LISBOA 157 53 65/35 88% 
Table 1. Nasopharyngeal carcinoma in Portugal 
It is also known that nonkeratizing NPC has a male preponderance and occurs earlier in life 
than head and neck carcinomas (Parkin DM 2002). These aspects are quite intriguing, as 
none of the commonly cited endogenous and exogenous risk factors for NPC seem to be 
directly linked to gender or age of cancer development. 
Familial clustering has also been frequently reported (Zhang and Zhang 1999), and can be 
explained by the demonstration of correlation between the HLA haplotype and NPC 
susceptibility. However, these very interesting findings need also to be better understood. 
It has been hypothesized that certain HLA polymorphic antigens have lower efficiency in 
activating the cytotoxic T cell recognition and host immune response to EBV infection (Lu, 
Day et al. 1990; Lo, To et al. 2004). In this context, potential role of the MHC class I chain–
related A (MICA) gene belonging to the nonclassical HLA family and located 46 kb 
centromeric to the human leukocyte antigen (HLA)–B gene is of particular interest. MICA is 
highly polymorphic, with more than 60 alleles (defined by nucleotide substitutions within 
exons encoding the three alfa-domains) described to date. Each of these variants is 
characterized by the presence of a variable number of short tandem repeats (STRs) within 
the exon encoding for the transmembrane region of the molecule(Douik, Ben Chaaben et al. 
2009).There are multiple evidences that the MICA*A9 is linked with several of those HLA 
haplotypes NPC related (HLA-B35, -B38, -B39, -B51, -B58) (Chan, Day et al. 1983; Wu, 
Hwang et al. 1989; Zhu, Chen et al. 1990; Tian, Boggs et al. 2001). 
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Wei Tian et al (Tian, Zeng et al. 2006) demonstrated a positive association between 
MICA*A9 and nasopharyngeal carcinoma, only observed in male subjects, and this finding 
had statistical significance (P=0.0001). This fact is not well explained, but it should be 
remembered that HLA genes are sex-linked and transmitted in bloc. 
Furthermore, a recent study demonstrated the existence of a binding site in the long intron 1 
of the MICA gene for NF-kappaB (Molinero, Fuertes et al. 2004). It has been shown that 
physiologic concentrations of male hormones (androgens) cause prolonged NF-kappaB 
DNA binding activities, which are diminished by vitamins C and E (Ripple, Henry et al. 
1999)and estrogen inhibits NF-kappa B activity (Ghisletti, Meda et al. 2005; Kalaitzidis and 
Gilmore 2005). These findings are mostly fascinating when we consider that TRAF is 
activated by the LMP1 latent EBV protein. 
The NPC age distribution is also quite different than usual, and seems to vary according to 
the incidence. It is accepted that in low-risk countries, the NPC incidence rises 
monotonically with age, but in high-risk regions the age incidence hit the highest point at 55 
years(Chang and Adami 2006), showing bimodal age presentation in Northern Africa and 
India (Bray, Haugen et al. 2008). These results also need an explanation, namely on the 
influence of some genetic polymorphisms that may influence the age of onset of disease 
(Catarino, Pereira et al. 2008; Sousa H 2010). 
The close relationship between nonkeratinizing NPC and EBV is sustained by “in-situ” 
hybridization studies (Wei and Sham 2005) and occurs both in endemic as in non-endemic 
countries (Niedobitek, Hansmann et al. 1991; Breda, Catarino et al. 2010). However, 
infection with EBV is a worldwide phenomenon and other endogenous and exogenous 
factors must be associated with NPC development. The relative weight of these factors is not 
yet clearly understood, namely in non-endemic regions. 
4.3 NPC stage classification and prognostic evaluation 
Whatever its localization, cancer prognosis will conceptually depend on biological 
aggressiveness of tumor itself, host characteristics and therapeutic options.  
The tumor, node, metastasis (TNM) staging system, allows clinicians to categorize tumors of 
the head and neck region in a specific manner, to assist with the assessment of disease 
status, prognosis and management (Daniel G. Deschler 2008). The introduction of several 
clinical staging systems (American Joint Committee on Cancer (AJCC) staging, the 
International Union Against Cancer (UICC) staging, Ho’s staging from Hong Kong, Fuzhou 
staging from Mainland China, Huang’s or Hsu’s staging from Taiwan), permitted that TNM 
staging for NPC remained relatively confused during many years and this was undesirable. 
It is accepted that a good TNM classification should fulfill the following criteria:(1) the 
subgroups defined by T, N, and M that make up a given group within a grouping scheme 
must have similar survival rates (hazard consistency); (2) the survival rates must differ 
among the groups (hazard discrimination); (3) the prediction of cure must be high (outcome 
prediction); and (4) the distribution of patients among the groups must be balanced 
(Groome, Schulze et al. 2001). The association between the AJCC and UICC staging systems 
and their succeeding modifications taking into account the criteria previously enunciated, 
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namely with rearrangements on T and N arrays, allowed a better TNM prognostic 
significance in the most recent classifications (Liu, Tang et al. 2008). 
However, NPC TNM classification only takes into account the aggressiveness of the 
“clinical” tumor; understand all the factors influencing the clinical course of NPC in order 
to improve the TNM classification (Greene, Page et al. 2002) and anticipate NPC 
prognosis, is still a challenge, recognized by several authors (Lee, Au et al. 2004; Liu, Tang 
et al. 2008). Accordingly, other tumor characterystics may confirm relevance on prognosis, 
suhc as histological types (WHO type II and III versus type I). Furthermore, taking into 
account the relationship between histological types and EBV, it also seems to be very 
interesting to know how relevant can be the measurement of EBV related proteins in the 
patient’s serum as a prognostic factor of survival. Plasma EBV-DNA measurement is 
actually believed to be a more sensitive and specific marker than the serum IgA/VCA 
titer for the diagnosis and monitoring of patients with NPC (Shao, Li et al. 2004). Even 
more, plasma EBV-DNA findings provide convincing evidence of their usefulness on the 
early diagnosis and staging of NPC as well as for monitoring recurrence and metastasis of 
this tumor. Some studies indicate that high marker level (>500 copies/ml) at 6 weeks after 
radio(chemo)therapy is a powerful prognosticator of recurrence, whereas pretreatment 
EBV DNA is a better discriminator of prognosis than conventional TNM classification for 
stage II NPC (Haddad 2011). 
Patient’s related prognostic factors are seldom referred in literature. Some authors claim 
that patients with younger age are associated with improved overall survival. One study 
involving 2,054 NPC patients from several European countries also showed that overall 
survival declined with age (Jiong, Berrino et al. 1998), and other series from endemic 
regions demonstrated similar results (Leung, Tung et al. 2005) (Liu, Tang et al. 2008). 
However, not always is disentangled age with better performance status and less 
comorbidity characteristics, more often present in younger patients, which might 
contribute to better tolerance to radical radio(chemo)therapy, thus resulting in better 
survival.  
The relationship between gender and prognosis is subject to similar doubts (Leung, Tung et 
al. 2005) (Liu, Tang et al. 2008) with controversial results being described. Again, it is 
difficult to straighten out gender with lifestyle (including body weight, central adiposity, 
physical activity, exposure to smoking, fruit and vegetable intake a.s.o. and these aspects 
still wait for clarification. 
4.4 NPC treatment, survival rate and quality of life 
Radiation therapy (RT) is considered the mainstay treatment for NPC. Recent retrospective 
analysis including more than two thousand patients treated by RT alone (mostly using 2D 
technique) showed that the 5-year overall survival (OS) was 85% for stages I–II (Lee, Sze et 
al. 2005), corroborating that NPC is highly sensitive to ionizing radiation. However, the 
same study demonstrated an OS of only 66% for stages III–IVB, with metastatic rate 
remaining high (25% at 5-years) for patients who achieved locoregional control, and these 
findings supported the need of some kind of systemic treatment, namely for advanced 
disease. 
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The advantages of adding chemotherapy (Ch) to RT had already been accomplished by the 
Intergroup 0099 study, the first prospectively randomized study to demonstrate an 
improvement in OS from the addition of concurrent chemotherapy and adjuvant 
chemotherapy to radiation therapy (when compared with radiation therapy alone), without 
unacceptably increasing the toxicity of treatment (Al-Sarraf, LeBlanc et al. 1998). 
From that time on, several trials confirmed not only that the addition of chemotherapy 
concurrent with radiation therapy has improved the outcomes of patients with NPC, but 
also that improvements in radiation treatment technology and the adoption of IMRT 
(Intensity-Modulated Radiation Therapy) have also improved local control, reducing also 
the morbidity.  
Besides the superior dose conformity delivered to tumor, one of the most important 
promised advantages of IMRT is the achievement of sufficient sparing of critical normal 
structures adjacent to treated areas, namely spinal cord, parotid glands, temporomandibular 
joint, middle and inner ears, skin (in the region of the target volumes), and oral cavity, 
mandible, glottic larynx, brachial plexus, and esophagus (including postcricoid pharynx) 
(Brady, Heilman et al. 2010) and such sparing has obvious advantages.  
However, even with IMRT, minor salivary glands and both palatal and masticator muscles 
(medial pterygoid and lateral pterygoid) are often included in target volumes, either gross 
tumor volume (GTV), clinical target volume (CTV) or planned target volume (PTV). The 
impact of such distresses on Quality of life (QoL) seems not to be disentangled enough 
(Bhatia, King et al. 2009; Lee, Harris et al. 2009).  
Quality of life refers to the perception of the effects of disease and its impact on the patient’s 
daily functioning; QoL is a multi-dimensional issue, incorporating physical, psychological, 
social and emotional domains, and it must be self-reported according to the patient’s own 
experiences (List and Stracks 2000). These very important mind and corporal approach is 
not often mentioned in scientific literature; usually, the endpoint of medical care for cancer 
patients is focused on the survival rate, local control rate, or complication rate. These 
endpoints were typically assessed from the physician’s points of view and lacked 
knowledge of patients’ mental or emotional well-being. According to Fang and co-workers 
(Fang, Tsai et al. 2010), in addition to socioeconomic levels, advanced RT techniques were 
observed to play a significant role in improving the QoL outcome of NPC survivors. 
However, the impact size from conventional 2DRT to 3DCRT or IMRT varied on different 
QoL scales. The therapeutic benefit of IMRT over 2DRT, especially on the swallowing-
related QoL scales, is not clear and should be further explored. 
One of the main aims of clinical or translational research in cancer is the search for biological 
factors that could foresee treatment outcomes, in biologic activity and toxic effects. The 
increasing amount of information regarding the role of genetics in human diseases has led 
to putative new biomarkers and the development of new fields, as pharmacogenomics 
(PGx). Pharmacogenomics is a rapidly developing scientific area, especially in oncology. In 
the most ideal situation, pharmacogenomics will allow oncologists to individualize therapy 
based on patients' individual germline genetic test results. This can help to improve efficacy, 
reduce toxicity and predict non-responders in a way that alternative therapy can be chosen 
or individual dose adjustments can be made. It has been observed that the interpatient 
variability in response to medications is associated with a spectrum of outcomes, ranging 
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from failure to demonstrate an expected therapeutic effect, to an adverse reaction resulting 
in significant patient morbidity and mortality, decreasing quality of life, as well as 
increasing healthcare costs. 
The goal of the emerging disciplines of pharmacogenomics is to personalize therapy based 
on an individual’s genotype. To date, the success of PGx has spread across all fields of 
medicine, although little is known about the genetic profile and its correlation with 
treatment response and overall survival in nasopharyngeal cancer patients. Genetic 
information has been used in the identification of disease risk, choice of treatment agents 
and guiding drug dosing. This is particularly important for chemotherapeutic agents, which 
in general affect both tumor and non-tumor cells and thus have a narrow therapeutic index, 
with the potential for life-threatening toxicity. Future work should explore the role of 
genetic variations in nasopharyngeal cancer patients, in a pharmacogenomics approach.  
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